MEDP - Earnings announcements

Revenue of $706.6 million in the first quarter of 2026 increased 26.5% from revenue of $558.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.3%. Net new business awards were $618.4 million in the first quarter of 2026, representing an increase of 23.7% from net new business awards of $500.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.88x. First quarter of 2026 GAAP net income was $123.9 million, or $4.28 per diluted share, versus GAAP net income of $114.6 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 17.5% and 20.5% for the first quarter of

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2026 financial results after the market close on Wednesday, April 22, 2026. The Company will host a conference call the following morning, Thursday, April 23, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

Revenue of $708.5 million in the fourth quarter of 2025 increased 32.0% from revenue of $536.6 million for the comparable prior-year period, representing a backlog conversion rate of 23.6%. Net new business awards were $736.6 million in the fourth quarter of 2025, representing an increase of 39.1% from net new business awards of $529.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Fourth quarter of 2025 GAAP net income was $135.1 million, or $4.67 per diluted share, versus GAAP net income of $117.0 million, or $3.67 per diluted share, for the comparable prior-year period. Net income margin was 19.1% and 21.8% for the fourth quarter

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2025 financial results after the market close on Monday, February 9, 2026. The Company will host a conference call the following morning, Tuesday, February 10, 2026, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniqu

Revenue of $659.9 million in the third quarter of 2025 increased 23.7% from revenue of $533.3 million for the comparable prior-year period, representing a backlog conversion rate of 23.0%. Net new business awards were $789.6 million in the third quarter of 2025, representing an increase of 47.9% from net new business awards of $533.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.20x. Third quarter of 2025 GAAP net income was $111.1 million, or $3.86 per diluted share, versus GAAP net income of $96.4 million, or $3.01 per diluted share, for the comparable prior-year period. Net income margin was 16.8% and 18.1% for the third quarter of 2

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2025 financial results after the market close on Wednesday, October 22, 2025. The Company will host a conference call the following morning, Thursday, October 23, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can

Revenue of $603.3 million in the second quarter of 2025 increased 14.2% from revenue of $528.1 million for the comparable prior-year period, representing a backlog conversion rate of 21.2%. Net new business awards were $620.5 million in the second quarter of 2025, representing an increase of 12.6% from net new business awards of $551.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.03x. Second quarter of 2025 GAAP net income was $90.3 million, or $3.10 per diluted share, versus GAAP net income of $88.4 million, or $2.75 per diluted share, for the comparable prior-year period. Net income margin was 15.0% and 16.7% for the second quarter o

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2025 financial results after the market close on Monday, July 21, 2025. The Company will host a conference call the following morning, Tuesday, July 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $558.6 million in the first quarter of 2025 increased 9.3% from revenue of $511.0 million for the comparable prior-year period, representing a backlog conversion rate of 19.2%. Net new business awards were $500.0 million in the first quarter of 2025, representing a decrease of 18.8% from net new business awards of $615.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.90x. First quarter of 2025 GAAP net income was $114.6 million, or $3.67 per diluted share, versus GAAP net income of $102.6 million, or $3.20 per diluted share, for the comparable prior-year period. Net income margin was 20.5% and 20.1% for the first quarter of 2025

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2025 financial results after the market close on Monday, April 21, 2025. The Company will host a conference call the following morning, Tuesday, April 22, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $536.6 million in the fourth quarter of 2024 increased 7.7% from revenue of $498.4 million for the comparable prior-year period, representing a backlog conversion rate of 18.3%. Net new business awards were $529.7 million in the fourth quarter of 2024, representing a decrease of 13.8% from net new business awards of $614.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 0.99x. Fourth quarter of 2024 GAAP net income was $117.0 million, or $3.67 per diluted share, versus GAAP net income of $78.3 million, or $2.46 per diluted share, for the comparable prior-year period. Net income margin was 21.8% and 15.7% for the fourth quarter of

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq

Revenue of $533.3 million in the third quarter of 2024 increased 8.3% from revenue of $492.5 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $533.7 million in the third quarter of 2024, representing a decrease of 12.7% from net new business awards of $611.5 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.00x. Third quarter of 2024 GAAP net income was $96.4 million, or $3.01 per diluted share, versus GAAP net income of $70.6 million, or $2.22 per diluted share, for the comparable prior-year period. Net income margin was 18.1% and 14.3% for the third quarter of 2024 a

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2024 financial results after the market close on Monday, October 21, 2024. The Company will host a conference call the following morning, Tuesday, October 22, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u

Revenue of $528.1 million in the second quarter of 2024 increased 14.6% from revenue of $460.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $551.0 million in the second quarter of 2024, representing a decrease of 4.1% from net new business awards of $574.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.04x. Second quarter of 2024 GAAP net income was $88.4 million, or $2.75 per diluted share, versus GAAP net income of $61.1 million, or $1.93 per diluted share, for the comparable prior-year period. Net income margin was 16.7% and 13.3% for the second quarter of

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2024 financial results after the market close on Monday, July 22, 2024. The Company will host a conference call the following morning, Tuesday, July 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $511.0 million in the first quarter of 2024 increased 17.7% from revenue of $434.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.2%. Net new business awards were $615.6 million in the first quarter of 2024, representing an increase of 10.8% from net new business awards of $555.8 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.20x. First quarter of 2024 GAAP net income was $102.6 million, or $3.20 per diluted share, versus GAAP net income of $72.9 million, or $2.27 per diluted share, for the comparable prior-year period. Net income margin was 20.1% and 16.8% for the first quarter of 2

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2024 financial results after the market close on Monday, April 22, 2024. The Company will host a conference call the following morning, Tuesday, April 23, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%. Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x. Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter o

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2023 financial results after the market close on Monday, February 12, 2024. The Company will host a conference call the following morning, Tuesday, February 13, 2024, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniq

Revenue of $492.5 million in the third quarter of 2023 increased 28.3% from revenue of $383.7 million for the comparable prior-year period, representing a backlog conversion rate of 19.1%. Net new business awards were $611.5 million in the third quarter of 2023, representing an increase of 29.9% from net new business awards of $470.9 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.24x. Third quarter of 2023 GAAP net income was $70.6 million, or $2.22 per diluted share, versus GAAP net income of $66.0 million, or $2.05 per diluted share, for the comparable prior-year period. Net income margin was 14.3% and 17.2% for the third quarter of 20

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2023 financial results after the market close on Monday, October 23, 2023. The Company will host a conference call the following morning, Tuesday, October 24, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be

Revenue of $460.9 million in the second quarter of 2023 increased 31.2% from revenue of $351.2 million for the comparable prior-year period, representing a backlog conversion rate of 18.7%. Net new business awards were $574.8 million in the second quarter of 2023, representing an increase of 27.6% from net new business awards of $450.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.25x. Second quarter of 2023 GAAP net income was $61.1 million, or $1.93 per diluted share, versus GAAP net income of $49.4 million, or $1.46 per diluted share, for the comparable prior-year period. Net income margin was 13.3% and 14.1% for the second quarter

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2023 financial results after the market close on Monday, July 24, 2023. The Company will host a conference call the following morning, Tuesday, July 25, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $434.1 million in the first quarter of 2023 increased 31.2% from revenue of $330.9 million for the comparable prior-year period, representing a backlog conversion rate of 18.6%. Net new business awards were $555.8 million in the first quarter of 2023, representing an increase of 31.4% from net new business awards of $423.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.28x. First quarter of 2023 GAAP net income was $72.9 million, or $2.27 per diluted share, versus GAAP net income of $61.3 million, or $1.69 per diluted share, for the comparable prior-year period. Net income margin was 16.8% and 18.5% for the first quarter of 20

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2023 financial results after the market close on Monday, April 24, 2023. The Company will host a conference call the following morning, Tuesday, April 25, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used

Revenue of $394.1 million in the fourth quarter of 2022 increased 27.7% from revenue of $308.6 million for the comparable prior-year period, representing a backlog conversion rate of 17.6%. Net new business awards were $485.1 million in the fourth quarter of 2022, representing an increase of 5.8% from net new business awards of $458.7 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x. Fourth quarter of 2022 GAAP net income was $68.7 million, or $2.12 per diluted share, versus GAAP net income of $50.0 million, or $1.32 per diluted share, for the comparable prior-year period. Net income margin was 17.4% and 16.2% for the fourth quarter of 2

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2022 financial results after the market close on Monday, February 13, 2023. The Company will host a conference call the following morning, Tuesday, February 14, 2023, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a uniqu

Revenue of $383.7 million in the third quarter of 2022 increased 29.8% from revenue of $295.6 million for the comparable prior-year period, representing a backlog conversion rate of 17.7%. Net new business awards were $470.9 million in the third quarter of 2022, representing an increase of 15.4% from net new business awards of $408.0 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x. Third quarter of 2022 GAAP net income was $66.0 million, or $2.05 per diluted share, versus GAAP net income of $48.6 million, or $1.29 per diluted share, for the comparable prior-year period. Net income margin was 17.2% and 16.4% for the third quarter of 20

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2022 financial results after the market close on Monday, October 24, 2022. The Company will host a conference call the following morning, Tuesday, October 25, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be u

Revenue of $351.2 million in the second quarter of 2022 increased 26.2% from revenue of $278.3 million for the comparable prior-year period, representing a backlog conversion rate of 16.8%. Net new business awards were $450.6 million in the second quarter of 2022, representing an increase of 16.3% from net new business awards of $387.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.28x. Second quarter of 2022 GAAP net income was $49.4 million, or $1.46 per diluted share, versus GAAP net income of $39.9 million, or $1.06 per diluted share, for the comparable prior-year period. Net income margin was 14.1% and 14.3% for the second quarter of

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its second quarter 2022 financial results after the market close on Monday, July 25, 2022. The Company will host a conference call the following morning, Tuesday, July 26, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, interested parties must register in advance by clicking on this link. While it is not required, it is recommended you join 10 minutes prior to the event start. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique PIN that can be used t

Revenue of $330.9 million in the first quarter of 2022 increased 27.3% from revenue of $260.0 million for the comparable prior-year period, representing a backlog conversion rate of 16.6%. Net new business awards were $423.0 million in the first quarter of 2022, representing an increase of 18.8% from net new business awards of $356.2 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.28x. First quarter of 2022 GAAP net income was $61.3 million, or $1.69 per diluted share, versus GAAP net income of $43.3 million, or $1.14 per diluted share, for the comparable prior-year period. Net income margin was 18.5% and 16.7% for the first quarter of 2022

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its first quarter 2022 financial results after the market close on Monday, April 25, 2022. The Company will host a conference call the following morning, Tuesday, April 26, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 3191816. To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide presen

Revenue of $308.6 million in the fourth quarter of 2021 increased 18.8% from revenue of $259.7 million for the comparable prior-year period, representing a backlog conversion rate of 16.7%; Full year 2021 revenue of $1,142.4 million increased 23.4% from full year 2020. Net new business awards were $458.7 million in the fourth quarter of 2021, representing an increase of 27.9% from net new business awards of $358.6 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.49x; Full year 2021 net new business awards of $1,610.4 million increased 37.1% from the prior year. Fourth quarter of 2021 GAAP net income was $50.0 million, or $1.32 per diluted sh

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its fourth quarter and fiscal year 2021 financial results after the market close on Monday, February 14, 2022. The Company will host a conference call the following morning, Tuesday, February 15, 2022, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 9164466. To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A su

Revenue of $295.6 million in the third quarter of 2021 increased 28.3% from revenue of $230.4 million for the comparable prior-year period, representing a backlog conversion rate of 17.0%. Net new business awards were $408.0 million in the third quarter of 2021, representing an increase of 29.4% from net new business awards of $315.4 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.38x. Third quarter of 2021 GAAP net income was $48.6 million, or $1.29 per diluted share, versus GAAP net income of $41.5 million, or $1.09 per diluted share, for the comparable prior-year period. Net income margin was 16.4% and 18.0% for the third quarter of 2021

Medpace Holdings, Inc. (NASDAQ:MEDP) ("Medpace") today announced that it will report its third quarter 2021 financial results after the market close on Monday, October 25, 2021. The Company will host a conference call the following morning, Tuesday, October 26, 2021, at 9:00 a.m. ET to discuss these results. To participate in the conference call, dial 800-219-7113 (domestic) or 574-990-1030 (international) using the passcode 5177474. To access the conference call via webcast, visit the "Investors" section of Medpace's website at investor.medpace.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. A supplemental slide pr

Revenue of $278.3 million in the second quarter of 2021 increased 35.8% from revenue of $205.0 million for the comparable prior-year period, representing a backlog conversion rate of 17.1%. Net new business awards were $387.6 million in the second quarter of 2021, representing an increase of 52.5% from net new business awards of $254.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.39x. Second quarter of 2021 GAAP net income was $39.9 million, or $1.06 per diluted share, versus GAAP net income of $24.1 million, or $0.64 per diluted share, for the comparable prior-year period. Net income margin was 14.3% and 11.8% for the second quarter of